PHS
STLN

Pekin Hardy Strauss’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Pekin Hardy Strauss’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Hold
32,000
– – 0.02% 481
2026
Q1 		$98.2K Buy
32,000
+22,000
+220% +$67.5K 0.01% 459
2025
Q4 		$35.6K Buy
+10,000
New +$37.1K ﹤0.01% 450

Other funds holding STLN

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
KWA
Kingswood Wealth Advisors San Diego, California $2.48B AUM 36.19% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
IAAG
Innovative Asset Advisors Group Shelton, Connecticut $229M AUM

Pekin Hardy Strauss's STLN Position: Q2 2026 in Review

Pekin Hardy Strauss held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q2 2026 at 32,000 shares worth $174K. The position accounts for 0.02% of the portfolio, ranked #481.

Pekin Hardy Strauss first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. 29 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Pekin Hardy Strauss held 32,000 shares of Starling Oncology Institute, Inc. Common Stock worth $174K as of Q2 2026.
  • Pekin Hardy Strauss left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q2 2026.
  • Starling Oncology Institute, Inc. Common Stock made up 0.02% of Pekin Hardy Strauss's portfolio in Q2 2026, its #481 holding.
  • Pekin Hardy Strauss first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2025 and has held it in 3 quarters since.
  • 29 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.